Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

Metabolic balance studies were done before and after each treatment period to assess the primary endpoint.

Why It Was Studied

Patients with short bowel syndrome might have impaired postprandial endogenous glucagon-like peptide-2 (GLP-2) secretion, which is required for optimal intestinal adaptation.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

An unmasked statistician generated the randomisation list, and the trial investigator enrolled patients and assigned them their patient numbers.

Trial investigators, patients, and other care providers were masked throughout the trial.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

The primary endpoint was the absolute change from baseline in faecal wet weight output, measured separately over the two treatment periods.

Safety analysis was by intention to treat.

This trial is registered at ClinicalTrials.gov, number NCT02690025, and has completed.

What Was Measured

Patients with short bowel syndrome might have impaired postprandial endogenous glucagon-like peptide-2 (GLP-2) secretion, which is required for optimal intestinal adaptation.

Topics PubMed links to this paper include Abdominal Pain, Anorexia, Colitis, Ulcerative, Crohn Disease, Edema, Enterostomy and Fatigue.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (The lancet. Gastroenterology & hepatology), a journal based in Netherlands.

More context: the Glucagon compound page, all human trials.